Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.4 HKD | +2.10% | -1.08% | -3.16% |
Business Summary
Number of employees: 4,872
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody and Protein Medicine, Pharmaceutical Products and Consultation and Research and Development
100.0
%
| 5,299 | 100.0 % | 6,858 | 100.0 % | +29.43% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
92.7
%
| 4,806 | 90.7 % | 6,357 | 92.7 % | +32.29% |
United States
7.1
%
| 478 | 9.0 % | 489 | 7.1 % | +2.32% |
Others
0.2
%
| 15 | 0.3 % | 11 | 0.2 % | -24.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
Fei You
DFI | Director of Finance/CFO | 45 | Feb. 04 |
Yong-Jun Liu
PSD | President | - | 20-10-14 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-31 |
Qin Wei Zhou
COO | Chief Operating Officer | 61 | 16-06-15 |
Hao Xi Ede
BRD | Director/Board Member | 65 | 17-06-04 |
Vivian Zhang
HRO | Human Resources Officer | - | 12-02-29 |
Blake Salisbury
PRN | Corporate Officer/Principal | - | 16-02-29 |
Yan Ju Wang
SEC | Corporate Secretary | 36 | 15-09-30 |
Lok Yee Chan
SEC | Corporate Secretary | 35 | 18-06-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Zieziula
BRD | Director/Board Member | 69 | 22-05-30 |
Charles Cooney
BRD | Director/Board Member | 80 | 15-10-17 |
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
I Yin Hsu
BRD | Director/Board Member | 50 | 18-10-17 |
Hao Xi Ede
BRD | Director/Board Member | 65 | 17-06-04 |
Kai Xian Chen
BRD | Director/Board Member | 78 | 18-10-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,627,101,801 | 1,513,725,962 ( 93.03 %) | 0 | 93.03 % |
Company contact information
Innovent Biologics, Inc.
168 Dongping Street Suzhou Industrial Park
215123, Suzhou
+86 512 6956 6088
http://www.innoventbio.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.16% | 8.62B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- 1801 Stock
- Company Innovent Biologics, Inc.